Historically, SHP2 has been an elusive molecular target; however, the advent of allosteric inhibitors has allowed for the development of TNO155, an orally bioavailable, first-in-class allosteric inhibitor of SHP2, to be examined in patients with advanced solid tumors, including BRAF/NRAS wild-type melanoma. This evidence concerns the gene BRAF and melanoma.